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ABSTRACT High relaxivity macromolecular contrast agents based on the conjugation of gadolinium 
chelates to the interior and exterior surfaces of MS2 viral capsids are assessed. The proton nuclear 
magnetic relaxation dispersion (NMRD) profiles of the conjugates show up to a five-fold increase in 
relaxivity, leading to a peak relaxivity (per Gd3+ ion) of 41.6 mM-1s-1 at 30 MHz for the internally 
modified capsids. Modification of the exterior was achieved through conjugation to flexible lysines, 
while internal modification was accomplished by conjugation to relatively rigid tyrosines. Higher 
relaxivities were obtained for the internally modified capsids, showing that (i) there is facile diffusion of 
water to the interior of capsids and (ii) the rigidity of the linker attaching the complex to the 
macromolecule is important for obtaining high relaxivity enhancements. The viral capsid conjugated 
gadolinium hydroxypyridonate complexes appear to possess two inner-sphere water molecules (q = 2) 
and the NMRD fittings highlight the differences in the local motion for the internal (τRl = 440 ps) and 
external (τRl = 310 ps) conjugates. These results indicate that there are significant advantages of using 
the internal surface of the capsids for contrast agent attachment, leaving the exterior surface available 
for the installation of tissue targeting groups. 
MANUSCRIPT TEXT  
 Magnetic resonance imaging (MRI) is a routinely used noninvasive diagnostic technique, 
providing detailed images without the use of ionizing radiation. Although the resolution of MRI is 
excellent, its dynamic range is relatively narrow because of the limited variation in relaxation rates 
exhibited by water protons in vivo. When these differences are insufficient to distinguish between 
adjacent tissues, contrast enhancement is often achieved through the administration of synthetic agents 
that increase the water proton relaxation rates in accessible locations. Gadolinium complexes are the 
most often used for this purpose, with more than 10 million MRI studies being performed through their 
use each year.2-4 The current commercially available Gd(III)-based contrast agents use poly(amino-
carboxylate) chelates, and typically gram quantities of Gd must be injected to reach concentrations 
sufficient for usable contrast enhancement. However, this strategy is more difficult to apply to the 
specific imaging of biomarkers present in low (μM - nM) concentrations. To distinguish these sites 
from the background signal, targetable contrast agents will undoubtedly require significantly improved 
contrast enhancement efficiencies.3, 5 
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 MRI contrast agents are commonly evaluated on the basis of relaxivity (r1p), which describes 
their ability to increase the longitudinal relaxation rate of nearby water molecule protons per millimolar 
concentration of agent applied.6 Strategies for enhancing the relaxivity of contrast agents include 
increasing the number of bound water molecules (q), optimizing the water-residence time (τM) and 
increasing the rotational correlation time (τR) by attachment to macromolecules or nanoparticles. The 
first two parameters have been optimized successfully in Gd hydroxypyridonate (HOPO) based contrast 
agents, and when attached to macromolecules relaxivities as high as 200 mM-1s-1 per Gd (peaking 
between 20-100 MHz, with q = 2, rGd-H = 3.1 and electronic relaxation times T1e = 15 ns, T2e= 0.3 ns) 
can theoretically be obtained for these complexes.7  For HOPO based and other complexes, relaxivity 
enhancement has been demonstrated through the attachment of contrast agents to proteins,8-10 
polypeptides,11 dendrimers,12, 13 nanospheres,14 and micellar nanoparticles.15-17 Nanometer scale contrast 
agents also offer the potential to differentiate non-nervous-system tissue. They should be large enough 
to be retained in blood capillaries by normal endothelial barriers, and yet they should diffuse across the 
distorted endothelium associated with pathological lesions.9, 11 Studies have shown that particles larger 
than 10 nm should be able to permeate preferentially through tumor tissues.11 
 Recently, several groups have explored the idea of using the protein coats of viruses as potential 
nanoparticles for the development of nanometer scale MRI contrast agents. The availability of two 
surfaces (inside and outside) can allow the independent attachment of imaging and targeting agents to 
the same scaffold, providing an advantage over most common approaches to macromolecular contrast 
agents. The first demonstration of this concept involved the chelation of Gd3+ ions to Ca2+ binding sites 
in the protein coat of the cowpea chlorotic mottle virus (CCMV, 28.5 nm diameter). The resulting 
particles exhibited exceedingly high relaxivities (r1p = 202 mM
-1s-1 per Gd ion at 61 MHz),18 but 
clinical applications will require improvements in metal binding affinity to avoid the toxicity of free 
gadolinium. Another study involved the conjugation of Magnevist (Gd-diethylenetriaminopentaacetic 
acid, Gd-DTPA) isothiocyanate to lysine residues of MS2 virus capsids.19 The resulting relaxivity was 
14 mM-1s-1 per Gd ion, with a total molecular relaxivity of 7200 mM-1s-1 at 64 MHz. 'Click chemistry' 
has also been used for the covalent attachment of Gd(DOTA) to lysine residues, in conjunction with the 
natural affinity of Gd3+ ions for the polynucleotide encapsulated within the capsids. These conjugates 
exhibited similar relaxivities (11-15 mM-1s-1 per complex at 64 MHz).20  
 These examples demonstrate that viral capsids offer significant potential for building nanometer 
scale contrast agents with very high overall relaxivities. They also indicate that a balance must be struck 
between the high relaxivity of weakly bound Gd3+ and the need for strong chelators that reduce toxicity 
at the expense of available water exchange sites. Several factors related to the linking strategy (such as 
the rigidity of the linkers, the interaction of Gd-complexing ligands with protein residues, and the 
flexibility of the protein region containing the amino acid being modified) may also affect the overall 
relaxivity values in complex ways.21-24 Therefore, detailed studies of the relaxometric properties are 
needed to determine the influence of these factors.  
To do this, we report herein a detailed analysis of the NMRD profiles and physical parameters of 
two viral-capsid based contrast agents.  Recently we have described the covalent attachment of HOPO 
based chelates to either the exterior or the interior surface of bacteriophage MS2 capsids devoid of 
nucleic acids.25 The MS2 capsid shell consists of 180 copies of the coat protein (MW = 13.7 kDa) 
assembled into an icosahedral arrangement (diameter 27 nm). A Gd3+ ligand suitably functionalized for 
selective bioconjugation (1) was prepared by attaching an alkoxyamine linker to a heteropodal TREN-
bis-HOPO-TAM ligand.26 This compound was then attached to capsids previously modified by 
attaching aldehyde groups to exterior amino groups (K106, K113, and the N-terminus, 540 total sites 
per capsid) or interior tyrosines (Y85, 180 total sites per capsid),27 Figure 1. Due to the lower solubility 
of the external conjugates, the number of ligands per capsid was chosen to be 90 (50% 
functionalization). The resultant conjugates were then metallated with Gd3+ to obtain the contrast agents 
shown in Figure 2.28 Free Gd3+ was removed through exhaustive dialysis against citrate buffer, as has 
been previously described.25 
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The Gd-HOPO chelates were chosen because they have at least 2-3 times higher relaxivities 
(between 8-14 mM-1s-1 at 20 MHz) than those of commercial agents, while maintaining similar 
stabilities (TREN-bis-HOPO-TAM-Me, pGd 20.1; Gd-DTPA, pGd 19.4).29-31 The higher relaxivities of 
the HOPO-based complexes are primarily due to an increased number of bound water molecules (q = 2 
or 3) and fast water exchange (τM typically between 5 and 30 ns32-34). These values represent exchange 
rates that are orders of magnitude faster than those of commercial complexes and are near optimal for 
attaining maximum relaxivities for molecules having very slow tumbling rates (e.g. oligomers and 
contrast agents attached to dendrimers). The initial relaxivity measurements on the Gd-HOPO-capsid 
conjugates gave relaxivities per Gd3+ ion as high as 41.6 mM-1s-1 (at 30 MHz and 25 ºC), values that 
represent some of the highest relaxivities yet reported for covalently modified virus-based contrast 
agents.  
 Anticipating the biological relevance of these studies, full relaxometric data have been obtained 
at both 310 and 298 K. The change of relaxivity with magnetic field is a NMRD profile that can be 
fitted to the appropriate model describing the magnetic coupling of the solvent with the system. 
Important parameters, such as q, τM, and τR that affect relaxivity can then be obtained from the fits. The 
NMRD profiles for the externally and internally modified HOPO-capsid conjugates compared to that of 
small molecule chelate Gd-TREN-bis-HOPO-TAM-CO2H are shown in Figures 3 and 4.
30 The 
maximum relaxivities obtained were 30.7 mM-1s-1 (30 MHz, 25 ºC) for the externally modified capsids 
and 41.6 mM-1s-1 (30 MHz, 25 ºC) for the internally modified capsids. This represents a four to five fold 
increase in relaxivity upon attachment of the Gd-TREN-bis-HOPO-TAM chelate to virus capsids in 
comparison to Gd-TREN-bis-HOPO-TAM-CO2H. The relaxation rate of unlabeled MS2 was measured 
to be ca. 0.4-0.5 s-1 and showed a negligible dependence on the magnetic field strength. The relaxivity 
values decrease (27.8 mM-1s-1 for external and 38.9 mM-1s-1 for internal modification, at 30 MHz) upon 
increasing the temperature to 37 ºC, suggesting that the relaxivity enhancements observed upon 
conjugation to the MS2 capsids are not limited by a slow rate of water exchange from the inner 
coordination sphere of Gd(III), but rather by the tumbling rate. The temperature dependence of 
relaxivity (r1p, longitudinal relaxivity) for the externally and internally modified capsids at 20 MHz is 
shown in Figure 5. The exponential decrease of relaxivity with increasing temperature is consistent with 
slowly tumbling systems with fast-exchanging inner-sphere water molecules. 
 Solomon-Bloembergen-Morgan theory connects the macroscopic relaxivity to the intrinsic 
parameters of the Gd(III) complexes.6, 35 High frequency data (2-70 MHz) were fitted to this 
relationship for paramagnetic relaxation, modified in terms of the Lipari-Szabo approach for the 
description of the rotational dynamics.36-38 This model considers two types of motion that influence the 
magnetic relaxation:  global motion of the system described by a global reorientation correlation time 
τRg, and  faster local motion with a local reorientation correlation time τRl. An additional parameter, S2, 
describes the extent of spatial restriction of the local motion (or the coupling of local and global 
motions); S2 = 1 when the Gd-complex is completely immobilized (τRg = τRl), and S2 = 0 when the local 
motion is totally independent of the global motion of the system. The parameters for electronic 
relaxation (Δ2, τV) were used as empirical fitting parameters and do not have a precise physical meaning 
in this model. For this reason, these parameters were not forced to be identical for the internal and 
external conjugates. The outer-sphere component of the relaxivity was estimated on the basis of the 
Freed equation by using standard values for the distance of closest approach a and the relative diffusion 
coefficient of solute and solvent D.6  
 The parameters that gave the best fit for the NMRD profiles are listed in Table 1. The number of 
inner sphere molecules (q) has been reported as 2 for the TREN-bis-HOPO-TAM complexes. The q 
value is reliably estimated by analysis of the NMRD profiles and by comparison of the relaxivity data 
for a large series of related complexes.30 The validity of the relaxometric evaluation of the hydration 
number has been confirmed through the direct measurement of q by luminescence in the case of 
EuTACN-1,2-HOPO (q = 3)33 and Eu-H(2,2)-1,2-HOPO (q = 1).39 The NMRD profile fits for the 
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conjugates were obtained by fixing q to 2. Although the hypothesis that both conjugated complexes 
possess q=1 cannot be excluded on the basis of the relaxometric data, the assumption of two bound 
water molecules gave the best fits (Supporting information Figure S1) for both the internally and 
externally modified capsids, and is consistent with other TREN-bis-HOPO-TAM derivatives.7, 30 The 
distance of the coordinated water molecules from the metal ion (rGd-H) was fixed to 3.1 Å.
40 Based on 
the observed relaxivity dependence with temperature and on the analogy with other Gd-TREN-bis-
HOPO-TAM derivatives, the mean residence lifetime τM was fixed to 10 ns (Supporting information 
Figures S2 and S3).30 Facile diffusion of water to the interior of the capsid is implied by the result that 
the best NMRD fits for 4 and 5 (internal conjugates 5 with slightly higher relaxivity values, compared 
to external conjugates 4) were for the same q value for both conjugates. The internal conjugates also 
have greater solubility than the external conjugates, and hence present the advantage of attaching 
solubilizing and targeting groups to the exterior.25  
 The τR value for Gd-TREN-bis-HOPO-TAM-CO2H has been reported as 94 ps at 298 K (Table 
2).30 The local reorientation correlation times (τRl) can be compared to the τR value for the small 
molecule complex and is 3 to 4 times slower for the conjugates (310 ps for the external and 440 ps for 
the internal conjugates). Also, the value for the internal conjugates is 1.4 times slower than the external 
conjugates. The external conjugates were obtained by covalent linkages to lysines, while the internal 
conjugates were obtained by forming covalent linkages to tyrosines. Targeting a rigid aromatic tyrosine 
residue side chain, rather than a more flexible aliphatic lysine side chain, reduces the number of free 
rotating σ-bonds between the Gd-chelate and the capsid surface. The increased rigidity of the tyrosine-
based bioconjugation strategy could be responsible for the slower τRl.  In addition, we must consider 
that the amount of protein structural fluctuation is different at the sites of attachment (Y85 versus the 
amino groups). The MS2 capsid shell is dynamic in solution, and motion about or around loop regions 
may affect τRl. The lysines are a part of α-helices and the tyrosines are a part of β-sheets, as shown in 
Figure 6, and the difference in the rigidities of these local protein environments can affect the τRl values 
(β-sheets being more rigid than α-helices). Thus, the τRl values reflect relatively accurately the local 
rigidity of the conjugates and hence the difference in relaxivities for the internal and external conjugates 
(the maximum relaxivity for the internal conjugates was 1.35 times higher than the external conjugates).  
 The global reorientation correlation times, τRg, should be very similar for the two conjugates as 
well as close to the rotational correlation time value of the MS2 virus capsid. This value has been 
reported to be close to 1 μs.41 The results of the NMRD fits were not sensitive to the τRg value in the 
range of 100 ns – 1 ms, so this value was set to 1 μs. The parameter S2, which indicates the effect of the 
global reorientation on local reorientation motion, or the coupling of the two motions, also has a low 
value in the range of 0.08-0.14. The values are again slightly higher for the internal conjugates, 
indicating greater coupling between the local and global motions.  
 The parameters obtained for these Gd-HOPO virus conjugates can be compared to the 
parameters reported for Gd-DOTA (commercially available as DOTAREM)42 dendrimer based 
conjugates, Gadomer 1721 and PAMAM-G4-[Gd(DOTA-pBn)(H2O)]
-
33
43 (Table 2). These dendrimeric 
conjugates are obtained through the covalent attachment of multiple Gd-DOTA units to polyamine 
based dendrimers. Their NMRD profiles have been analyzed according to the Lipari-Szabo approach.21, 
43 Gd-DOTA has a longer water-residence time (τM = 244 ns)42 than Gd-HOPO-based contrast agents 
(τM  = 10 ns), which inherently limits the relaxivity enhancements that can be attained upon conjugation 
to macromolecules. The τRl and S2 values for both of the dendrimer based conjugates are higher than 
those obtained for our virus based conjugates (indicating that these dendrimer based systems are more 
rigid that the capsid based systems), and the relaxivity enhancements (upon attachment to dendrimers) 
are in the range of 3.5 to 6.5 times those of the Gd-DOTA monomer (at 20 MHz and 25 °C). These 
relaxivity enhancements are similar to the values obtained for the virus-based conjugates (3.7 times for 
conjugate 4 and 5.3 times for conjugate 5 at 20 MHz relative to the Gd-HOPO monomer); however this 
cannot be completely explained by the τRl and S2 values, which are lower for virus based systems. For 
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example, conjugate 4 has τRl = 310 ps and S2 = 0.08, while Gadomer 17 has τRl = 760 ps and S2 = 0.5, 
even though slightly greater relaxivity enhancements are observed for conjugate 4. 
  Improved relaxivities are obtained in the Gd-DOTA based systems when the water exchange 
becomes faster, as in PAMAM-G4-[Gd(DOTA-pBn)(H2O)]
-
33, due to the presence of a pBn substituent 
on the Gd-DOTA that decreases the water residence time due to conformational or steric effects.43 The 
major difference in these systems is the mean water-residence lifetime (τM = 152 ns and 1000 ns for the 
Gd-DOTA dendrimer conjugates, while τM < ca. 50 ns for the Gd-HOPO virus conjugates). In the case 
of the Gd-DOTA based systems, the substitution position on the Gd-DOTA complex to create the 
attachment point to dendrimers affects the water residence time.21, 43 For Gd-TREN-bis-HOPO-TAM 
based systems, substituents on the TAM ligands lead to the water residence time in the range of 2-20 
ns30, and hence as mentioned previously τM = 10 ns was chosen for the virus conjugates to obtain the 
best fits for the NMRD profiles. The reason for the relaxivity enhancements observed can then be 
attributed to the optimal water exchange rates (in addition to the slow rotational correlation times) for 
the Gd-HOPO based systems, which would also lead to improved relaxivities for these macromolecular 
contrast agents at higher field strengths when compared to Gd-DOTA based system.7, 42 
 The NMRD profiles and the temperature dependence studies of these capsid systems indicate 
that they can be further improved to provide systems with sufficiently high relaxivity for biomarker 
targeting. Theoretical predictions for these systems (Figure 7) indicate that upon increasing the local 
reorientation correlation through the use of more rigid linkers, the relaxivity values can be increased to 
140 mM-1s-1 per Gd3+ ion at clinically relevant fields. Linking through tyrosine residues may be 
inherently beneficial in this respect, since they have fewer rotatable bonds than lysines. The observation 
that water transport through the capsid shell is not rate limiting suggests that additional complexes can 
be installed to reach still higher total relaxivity, a concept that is enabled by the increased water 
solubility of the internally modified conjugates. According to the theoretical predictions (Figure 7) and 
our data at 60 MHz (Table 2), the relaxivity increase upon increasing the rigidity will be limited as we 
move to higher field strengths, for targeted imaging applications. Higher relaxivities can be attained in 
these cases by using Gd chelates with smaller τM values (1-2 ns) optimal for higher field strengths, in 
conjunction to rigid linkers. The use of the Gd-TACN-HOPO-based complexes with such optimal 
water-exchange rates and a higher number of inner sphere water molecules (q=3) 33 should enhance the 
obtained relaxivities, as predicted in this study. The generation of additional capsid conjugates that 
possess these properties is currently in progress in our laboratories. 
Experimental Section 
Field cycling relaxometry The water proton NMRD profiles were measured at 25 and 37 °C on a 
Stelar Fast Field-Cycling Spectrometer FFC−2000 (Mede, Pv, Italy) on about 0.2-0.4 mmol complex-
conjugated MS2 solutions in non-deuterated water. The 1H T1 relaxation times were acquired by the 
standard inversion recovery method with a typical 90° pulse width of 3.5 μs, using 16 experiments of 4 
scans. The reproducibility of the T1 data was ±4%. The temperature was controlled with a Stelar VTC-
91 airflow heater equipped with a calibrated copper–constantan thermocouple (uncertainty of ± 0.1 °C). 
The NMRD profiles were measured in the range of magnetic fields from 0.00024 to 1.6 T 
(corresponding to 0.01–70 MHz proton Larmor frequencies).  
 
Gd-content measurements: Mineralization Monitored by Relaxometry44 
The gadolinium concentration of the complex-conjugated MS2 solutions was measured by a 
relaxometric procedure (20 MHz and 25 °C). Three accurate determinations (each on 3 different 
samples of similar concentration, prepared by dilution) of the 1H longitudinal water proton relaxation 
rate (R1
obs) were made at pH=6.9 on ca. 0.2-0.5 mM aqueous solutions. A volume of 100 μL of each 
solution was then added to 100 μL of 70 % HNO3  directly into a 1.0 mL glass ampoule. After gentle 
centrifugation (to ensure complete mixing) of the resulting solutions (1500 rpm, 2 min) the ampoules 
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were sealed and heated at 120 °C for 5 days. This treatment ensures that all Gd(III) is solubilized. The 
R1 values (R1
*) were then measured again (three times) and the concentration of Gd(III) in the starting 
solutions calculated using the following expression: 
[Gd] = [(R1
* - 0.51)/13.99] × 2                (1) 
where 13.99 is the relaxivity (mM-1 s-1) of the Gd ion under identical experimental conditions and 0.51 
(s-1) the relaxation rate of the diamagnetic solution (1:1 water and HNO3 70 %). This procedure was 
validated either on two solutions of know concentration (GdDTPA and GdDOTA) or by comparing the 
relaxometric procedure with the ICP data (on GdDTPA). 
Variable temperature measurements The temperature dependence of the longitudinal water proton 
relaxation rates was measured on a Stelar Spin-Master spectrometer operating at a magnetic field 
strength of 0.47 T (corresponding to the proton Larmor frequency of 20 MHz). The standard inversion–
recovery pulse sequence (180° –τ –90°) was used. The samples (ca. 100 μL) were placed in 5 mm NMR 
tubes. The temperature was controlled by a Stelar VTC-91 air flow heater equipped with a copper–
constantan thermocouple. The desired temperature was set up either by the internal heater or by an 
attached liquid nitrogen evaporator (T<24 °C). The actual temperature was checked inside the 
probehead (uncertainty of ± 0.1 °C) by using a digital thermometer. 
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FIGURES 
 
 
 
 
 
 
 
 
 
Figure 1. Conjugation of the TREN-bis-HOPO-TAM ligand to the exterior (2, targeting K106, K113, 
and the N-terminus) and interior (3, targeting Y85) surfaces of empty MS2 capsids. The conjugation 
was controlled to give 90 ligands per capsid in both cases. 
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Figure 2. Externally (4) and internally (5) labeled macromolecular contrast agents obtained upon 
metallation of the capsid conjugates with gadolinium(III). The crystal structure of the MS2 virus capsid 
is shown,28 highlighting the amino groups on the exterior: red = K106, yellow = K113, and orange = the 
N-terminus. Y85 is highlighted in green on the interior surface. 
 
 
Figure 3. 1/T1 proton nuclear magnetic relaxation dispersion (NMRD) profiles (pH = 6.9) and fits for 
conjugate 4 at 25 ºC (filled circles) and 37 ºC (open diamonds), in comparison with the NMRD profile 
for Gd-TREN-bis-HOPO-TAM-CO2H at 25 ºC (filled triangles).
30 
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Figure 4. 1/T1 proton nuclear magnetic relaxation dispersion (NMRD) profiles (pH = 6.9) and fits for 
conjugate 5 at 25 (filled squares) and 37 ºC (open triangles), in comparison with the NMRD profile for 
Gd-TREN-bis-HOPO-TAM-CO2H at 25 ºC (filled circles).
30 
 
Figure 5.  Variable-temperature proton relaxivity for conjugates 4 (filled circles) and 5 (filled triangles) 
at 20 MHz. 
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Figure 6.  The locations of the modified protein residues shown in the exterior, side, and interior views, 
as mapped on a coat protein dimer. Y85 extends from a β-sheet in the interior, while K106 and K113 
extend from α-helices on the exterior, causing differences in the local environments of the amino acids 
being modified. 
 
 Figure 7. Theoretical predictions for the maximum relaxivity attainable if the linkages are further 
rigidified to restrict the local motion (modeled using the parameters obtained for the internal conjugates 
at 298 K).  
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TABLES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Fitting parameters for the NMRD profiles of the 
macromolecular complexes 4 and 5.
3.12.33.12.3D (105 cm2s-1)c
4.04.04.04.0a (Å)c
3.13.13.13.1rGd-H (Å)c
2222qc
0.14 ± 0.010.13 ± 0.010.09 ± 0.010.08 ± 0.01S2
10101010τ M (ns)c
1111τ Rg (μs)c
0.40 ± 0.010.44 ± 0.020.25 ± 0.010.31 ± 0.01τ Rl (ns)
21 ± 324 ± 234 ± 136 ± 2τ V (ps)
1.7 ± 0.11.6 ± 0.22.5 ± 0.42.4 ± 0.3Δ2 (1019 s-2)
38.941.627.830.7r1p (mM-1 s-1)b
310 K298 K310 K298 K
5a (interior)4a (exterior)
a determined in 12.5 mM HEPES buffer at pH 6.85. b relaxivity data 
at 30 MHz. c Parameter fixed prior to fitting. 
Table 2. Comparison of the parameters (at 25 °C) obtained for conjugates 4 and 5 with dendrimer based 
macromolecular contrast agents.
30.9
23.2
22.5
16.4
3.7
8.5
r1p(60 MHz)
(mM-1s-1)
This work38.40.13440100010Internal conjugate 5
This work27.30.08310100010External conjugate 4
4331.20.395503.10152PAMAM-G4-[Gd(DOTA-pBn)(H2O)]--33
2116.50.57603.051000Gadomer 17
424.74-77-244Gd-DOTA
307.3-94-10Gd-TREN-bis-HOPO-TAM-CO2H
Referencer1p(20 MHz)
(mM-1s-1)
S2τRl
(ps)
τRg
(ns)
τM
(ns)
Complex
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